Storage of motor memory involves the basal ganglia and more precisely the striatum, which receives afferents from all regions of the cerebral cortex. In Parkinsonian (MPTP) monkeys, we observed an increase in the dyskinetic response to dopaminergic agents when combined with opioid antagonists (naloxone or naltrexone) while morphine, attenuated the dyskinetic response. An interesting phenomenon observed after several acute co-administrations of naltrexone with dopaminergic agents was the manifestation of dyskinesias even after the injection of saline or naltrexone alone. However, this phenomenon was not observed when morphine was used in the same conditions. These unexpected observations concerning the acquisition of dyskinesias with saline or naltrexone alone, reported for the first time, might suggest the implication of a learning phenomenon in the induction of levodopa-induced dyskinesias.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.nbd.2005.01.006 | DOI Listing |
Drug Alcohol Depend
January 2025
Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, MD, USA.
Background: Kappa-opioid receptors (KOR) are hypothesized to be involved in mediating ongoing methamphetamine self-administration. Previous rat studies have demonstrated that treatment with the KOR antagonist nor-binaltorphimine (nor-BNI) decreases methamphetamine self-administration. However, KOR antagonist effects on methamphetamine self-administration in nonhuman primates are unknown.
View Article and Find Full Text PDFPsychopharmacology (Berl)
February 2025
Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA.
J Pharmacol Exp Ther
October 2024
Behavioral Neuroimaging Laboratory, McLean Hospital, Belmont, Massachusetts (F.B.d.M., S.J.K.) and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (F.B.d.M., S.J.K.)
Clinical reports suggest that the most effective strategies for managing opioid use disorder comprise a comprehensive treatment program of both pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective are not well characterized. This study examined whether the presence of an alternative reinforcer could alter the efficacy of Food and Drug Administration-approved opioid antagonist or agonist medications, as well as the nonopioid flumazenil, in decreasing oxycodone choice self-administration in nonhuman primates.
View Article and Find Full Text PDFAm J Physiol Regul Integr Comp Physiol
December 2024
Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Florida, United States.
Kratom (), containing the primary alkaloid mitragynine, has emerged as an alternative self-treatment for opioid use disorder. Mitragynine binds numerous receptor types, including opioid receptors, which are known to modulate food consumption. However, the ability of acute mitragynine to modulate food consumption remains unknown.
View Article and Find Full Text PDFEnviron Toxicol Pharmacol
September 2024
Department of Psychology, University of Kentucky, Lexington, KY, USA. Electronic address:
This study assessed the ability of α and α-adrenergic drugs to decrease fentanyl-induced locomotor and ventilatory depression. Rats were given saline or fentanyl, followed by: (1) naltrexone, (2) naloxone, (3) nalmefene, (4) α agonist phenylephrine, (5) α antagonist prazosin, (6) α antagonist BMY-7378, (7) α agonist clonidine, (8) α antagonist yohimbine or (9) vehicle. All µ-opioid antagonists dose-dependently reversed fentanyl-induced locomotor and ventilatory depression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!